Leukemia, Lymphocytic, Acute
30
2
2
11
Key Insights
Highlights
Success Rate
48% trial completion
Published Results
12 trials with published results (40%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
40.0%
12 terminated out of 30 trials
47.8%
-38.7% vs benchmark
7%
2 trials in Phase 3/4
109%
12 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (30)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
CD34+ Transplants for Leukemia and Lymphoma
Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT
DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy
Stem Cell Transplant for Hematological Malignancy
Post Transplant Donor Lymphocyte Infusion
Randomized Double Cord Blood Transplant Study
Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies
Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)
CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）
Stem Cell Transplantation for Hematological Malignancies
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
NOPHO ALL-2008 Pilot Study on Consolidation Therapy for Children and Adolescents With Acute Lymphoblastic Leukemia
Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)
Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia